ZVSA | ZyVersa Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1500 - 2.5400
52 Week Range	2.0800 - 62.30
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	320,692
Average Volume	141,608
Shares Outstanding	1,074,196
Market Cap	2,556,586
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-02-11

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	1,163.36
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	ZVSA

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZVSA's peers: ALLR, ATNF, BNTC, CELU, CMMB, CNSP, CRBP, CYCN, CYTO, DRMA, DRUG, CELZ, EVAX, EVGN, GOVX, IMMP, IMMX, INM, CYBN, JAGX, LEXX, LPCN, MEIP, NBTX, NBY, NCNA, PALI, PHGE, PHIO, PYXS, QLGN, REVB, RNAZ, RVPH, SMMT, SONN, SPRC, TCBP, TENX, VIRI, VYNE, XBIO, BIOR, CDIO, ERNA, ICU, EFTR, VECT, AVRO, HEPA, ZURA, NAVB, CARM

*Chart delayed

Analyzing fundamentals for ZVSA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ZVSA Fundamentals page.

Watching at ZVSA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZVSA Technicals page.